key: cord-0866459-f15ktset
authors: Gürlevik, Sibel Laçinel; Günbey, Ceren; Ozsurekci, Yasemin; Oygar, Pembe Derin; Kesici, Selman; Gocmen, Rahsan; Aydin, Orkun; Temucin, Çağrı; Tufan, Erennur; Terzi, Kıvanc; Baltu, Demet; Ozturk, Tugba Tastemel; Teksam, Ozlem; Ozen, Seza; Oguz, Kader Karlı; Cengiz, Ali Bulent; Yalnızoglu, Dilek
title: Neurologic manifestations in children with COVID-19 from a tertiary center in Turkey and literature review
date: 2022-02-18
journal: Eur J Paediatr Neurol
DOI: 10.1016/j.ejpn.2022.02.003
sha: e958e18aeaa6e4e76cbcf4ad11cba94fc28ee783
doc_id: 866459
cord_uid: f15ktset

BACKGROUND: Since December 2019, coronavirus disease 2019 (COVID-19) has become a global pandemic caused by highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although respiratory disease and multisystem inflammatory syndrome in children (MIS-C) are main clinical presentations in children, numerous neurological manifestations are being described increasingly. We aimed to investigate new onset neurological symptoms associated with SARS-CoV-2 in pediatric patients in order to establish a possible relationship as well as to understand the underlying pathophysiological mechanisms between SARS-CoV-2 infection and neurological findings. METHODS: We analyzed retrospectively children who had neurologic manifestations temporally associated with SARS-CoV-2 infection at Hacettepe University İhsan Doğramaci Children's Hospital. We performed a literature search between March 20, 2020 and March 30, 2021. Articles that report children with COVID-19 related neurological manifestations were included. RESULTS: We have observed 15 consecutive cases with new onset neurological manifestations along with confirmed SARS-CoV-2 infection. Age at hospitalization ranged from three months to 17 years. Ten patients had central nervous system involvement, and most common manifestation was encephalopathy (5/10), which is also one of the most common manifestations of the patients mentioned in the relevant 39 articles we reviewed. CONCLUSION: Children with COVID-19 can present with neurologic findings such as encephalopathy, seizures, cerebrovascular events as well as abnormal eye movements. Clinical suspicion and awareness are required to show the association between neurologic manifestations and COVID-19.

Two (13.3%) MIS-C patients had both central and peripheral nervous system involvement, 2 presenting with encephalopathy and developing critical illness neuromyopathy on the 7 th and 26 th 3 days of admission, respectively. 4 5

Nine (60%) patients had lumbar punctures; only three cerebrospinal fluids (CSF) were analyzed 7 for SARS-CoV-2 PCR and SARS-CoV-2 IgG, with negative results (Table 1) . Two patients had 8 high CSF protein levels attributed to lumbar puncture procedures being traumatic hence cross-9 contamination of CSF. Red blood cells were observed on direct microscopic examination. The 10 remaining patients' CSF samples direct microscopic examination did not reveal any cells. The neurophysiological findings of the cases are summarized in Table 2 He had no history of fever or respiratory symptoms. Both were asymptomatic during follow-up. 9

Swarz et al. (22) reported that a 9-year-old boy with no medical history presented with focal SE. 10 He was afebrile and had no meningeal irritation findings. Head CT was normal, and EEG showed 11 continuous delta slowing throughout the right hemisphere without epileptiform activity. In a case 12 series reported from Chile, one patient among 13 cases presented with SE (23 The most common published cases with nervous system involvement were in the United States of 8 America, followed by the United Kingdom, Chile, and Mexico (Supplementary Table 1 ). 9

In the present study conducted in a tertiary center involving case series of hospitalized children 2 and adolescents with COVID-19 and/or MIS-C, neurologic involvement incidence was 4.8%. 3

Most of the patients (80%, n=12) with neurologic findings were previously healthy and most of 4 the neurological manifestations (n=15) were transient and resolved at the time of hospital 5 discharge. Three patients had mild to moderate new neurologic disabilities persisting at discharge. 6

In both adults and children, a wide range of neurological symptoms have been reported, ranging 7 from relatively mild symptoms like fatigue, headache, and anosmia to more severe clinical 8 presentations like encephalopathy, seizures, and stroke (2-5). In these reports neurologic 9 symptoms varied by age; while seizures and status epilepticus observed in young patients, 10 headache, loss of taste and smell and fatigue were observed in older patients. Consistent with these 11 findings, four patients with seizures (three with para-infectious febrile seizure and one with 12 postinfectious afebrile SE) included in the study were young children. A 3-month-old girl had her 13 first seizure during the postinfectious period and had punctate diffusion restriction in the posterior 14 limb of the internal capsule on MRI. No other etiological factor than COVID-19 was diagnosed. 15

The clinical outcome was good, and all these patients were seizure-free during three-to-six-month 16 follow-up with monotherapy. They had no neurological sequelae (mRS:0). 17 SARS-CoV-2 virus was initially thought unable to pass through the blood-brain barrier (BBB) or 18 enter the nervous system. However, postmortem studies on the cerebral pathology of SARS-CoV-19 2 have identified that it could pass the BBB, and neuro-invasion could use olfactory nerve channels 20 and trans-synaptic viral transfer (10, 54). Also possible is a "Trojan horse" mechanism of the virus 21 using macrophages to enter the central nervous system (55). Neural cells, astrocytes, microglia, 22 and brain microvascular endothelial cells express ACE2, a SARS-CoV-2 spike (S) protein binding 23 receptor (10,11). Once inside the nervous system, the virus can infect those cells and cause neural 1 damage or inflammation. This might help to explain the para-infectious events. Possible 2 pathophysiological mechanisms of neurological involvement in our pediatric cases might be the 3 direct viral invasion of neuronal structures through infecting olfactory system, or through types 2 4 and 3 innate immune cells. The role and distribution of ACE-2 receptors of over different areas of 5 brain, especially brainstem should be considered in pathophysiology. Postinfectious inflammatory 6 processes, dysregulated cytokine cascade, autoimmunity, and vascular events including 7 thrombosis, infarction, or hemorrhages might be responsible for pathophysiology of neurological 8 involvement (56-58). 9

Few studies have suggested the role of cytokines in febrile seizures (59,60). Some have reported 10 that proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), and interferon-11 γ (IFN-γ) are increased in febrile seizures. We did not study the cytokine/chemokine profiles of 12 our cases because of the retrospective nature of the study. Cytokines were reported to play a role 13 in the pathophysiology of SARS-CoV-2 infection (61). They may also be involved in the 14 pathophysiology of COVID-19-related febrile or afebrile seizures. Important proinflammatory 15 cytokines such as IL-6, TNF-α, IFN-γ, and IL-17 have been linked to the pathogenesis of SARS-16

CoV-2 infection (62, 63). They may play a key role in epileptic pathogenesis. They also lead to 17 seizures by increasing glutamate and decreasing GABA in the cerebral cortex and hippocampus 18 (62, 64). Therefore, we hypothesize that proinflammatory cytokines might have a crucial role in 19 the pathogenesis of seizures due to SARS-CoV-2 both during the para-infectious and 20 postinfectious periods. 21

We observed global cerebral involvement in five MIS-C patients with severe encephalopathy. All 22 had changes in cognition: three had visual, auditory, or tactile hallucinations, and two were in a 23 delirium state for two days. Two MIS-C patients had meningeal irritation at admission. Two MIS-1 C patients with severe and progressive disease course had vascular findings on MRI. MRI of one 2 patient revealed infra-and supratentorial multiple microhemorrhages, suggestive of small-vessel The exaggerated cytokine release leading to endothelial damage, the hallmark of MIS-C 10 pathogenesis, might be responsible for the disruption of BBB (54, 65). 11

Previous case reports in children stated the association between COVID-19 and secondary ICP 12 (53). Consistently, in our series, one patient with increased ICP was diagnosed with secondary ICP 13 related with COVID-19. Another patient diagnosed with factor V Leiden homozygous mutation, 14 maintained on ASA and had a stroke history had increased ICP. He was diagnosed with acute 15 hydrocephalus due to a web formation in Aquaeductus Sylvius and underwent an endoscopic third 16 ventriculostomy. During the course of COVID-19 he did not have a new-onset stroke and his MRI 17 only revealed contrast enchantment. Therefore, we hypothesized that the web formed in the 18 Aquaeductus Sylvius might have resulted from inflammation associated with COVID-19. 19

Five patients had peripheral nervous system impairment: one had neuropathic pain, two 20 experienced primarily encephalopathy and developed critical illness neuromyopathy during the 21 hospital stay, and two had myositis and elevated CK levels. Severe inflammation, several 22 secondary effects of critical illness, medications and possibly direct effects of SARS-CoV-2 may 23 be responsible for peripheric nervous system involvement (66-68). A significant number of 1 patients with severe COVID-19 hospitalizations may be prolonged and may require mechanical 2 ventilation, anesthetic medications, hence they are at risk of developing acquired weaknesses such 3 as critical illness polyneuropathy, myopathy, and polyneuromyopathy. All conditions have been 4 reported in adults with COVID-19, and severe inflammation is suggested to increase the risk 5 (67,68). 6

So far, few data are available to describe SARS-CoV-2 specific CSF findings. In the present study, 7 nine patients had CSF analysis, four had seizures, two had encephalopathy during MIS-C, one had 8 secondary ICP, one had abnormal eye movements, and one underwent ventriculostomy for 9 hydrocephalus. Pleocytosis was not detected in any samples. SARS-CoV-2 PCR and antibody 10 testing could be studied in three out of the nine CSF samples, and all three were negative. Overall, 11

the results of CSF studies of our patients were consistent with non-infectious inflammation to induce expression of inflammatory responses such as cytokines, chemokines, and matrix 1 metalloproteases (70, 71). These findings could provide a preference for anti-inflammatory or 2 immunomodulatory treatment for neurological complications if supported by further studies. 3 We reviewed a broad range of severe neurological findings of pediatric patients, including central 4 nervous system diseases (such as ADEM, severe encephalopathy with corpus callosum splenial 5 lesions, seizures, ischemic strokes, cerebral venous sinus thrombosis, acute cerebral edema, and 6 central nervous system infections) and peripheral nervous system diseases (such as GBS, myelitis, 7 cranial neuropathies, and severe myositis) associated with SARS-CoV-2 infection. Neurologic 8 involvement associated with SARS-CoV-2 possibly have multiple underlying mechanisms leading 9

to para-or post-infectious events. The activation of cytokines and chemokines might be one of the 10 key processes of postinfectious neurological involvement in MIS-C patients. In our case series 11 severe encephalopathy observed in MIS-C patients resolved completely with anti-inflammatory 12 treatment. 13 Some recent studies have reported neuropilin-1 (NRP1) as a receptor for the SARS-CoV-2 spike 14 protein (72). Moutal et al. (73) reported that the SARS-CoV-2 spike protein interacts with NRP1 15 to induce signaling in nociceptors. This could be a mechanism for pain during or after SARS-CoV-16 2 infection; another hypothesis is high cytokine levels during severe COVID-19 or MIS-C (74). 17

These theories could support the peripheral nervous system involvement that we report in a patient 18 with neuropathic pain during MIS-C and patients with critical illness neuromyopathies. 19 20 Our study has several limitations, this single-center retrospective observational study spans a short 21 period. The full spectrum of the neurologic symptoms might have been underestimated in children, 22 especially in young children. Neuroimaging could not be obtained for all patients. We could not 23 have a continuous EEG monitoring, so we might have missed electrographic seizures. The follow-1 up period of patients is short. Nevertheless, we were able to demonstrate the outcomes of patients 2 with a formal scale. 

Neurological associations of COVID-19

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus 5 disease 2019: a review

COVID-19: A global threat to the nervous system

Neurologicalmanifestations of COVID-19: a systematic 10 review and metaanalysis of proportions

Neurological manifestations of COVID-13 19 and other coronavirus infections: A systematic review

COVID-19, SARS and MERS: A 17 neurological perspective